There was no statistically significant treatment difference in rates of recurrent severe exacerbations ( treatment ratio 0.92 [ 95 % CI : 0.58 , 1.45 ] ) and moderate/severe exacerbations ( 0.82 [ 0.64 , 1.06 ] ) between FP/SAL and SAL in the intent-to-treat population .